Dissecting aberrant functions of the ubiquitin proteasome system in the treatment-induced evolution of Mantle Cell Lymphoma (A04)

• Subject Area: Hematology, Oncology
• Term: from 2016 to 2020
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 278529602

Mantle cell lymphoma (MCL) and multiple myeloma (MM) are incurable B-cell malignancies. Major treatment modalities of both entities include DNA damaging agents, proteasome inhibitors and immunomodulatory drugs (IMiDs) whose anti-tumour activities and induced resistance mechanisms critically involve the ubiquitin proteasome system (UPS). This project therefore aims to dissect aberrant functions of the UPS that contribute to treatment-induced evolution of MCL and MM and unravel their role as new therapeutic targets and biomarkers.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms
• Applicant Institution: Ludwig-Maximilians-Universität München
• Co-Applicant Institution: Technische Universität München (TUM)
• Project Head: Professor Dr. Florian Bassermann